

wherein  $R_1$  is lower alkyl,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are individually selected from the group consisting of hydrogen, halogen and  $-\text{OSO}_2R_{10}$ , at least one of  $R_3$ ,  $R_4$  and  $R_5$  being  $-\text{OSO}_2R_{10}$ ,  $R_6$  is  $-(\text{CH}_2)_m-\text{SiR}_7\text{R}_8\text{R}_9$ ,  $R_7$ ,  $R_8$  and  $R_9$  are individually lower alkyl,  $R_{10}$  is lower alkyl unsubstituted or substituted with at least one halogen or aryl unsubstituted or substituted with at least one lower alkyl,  $m$  is an integer from 0 to 6 and its non-toxic, pharmaceutically acceptable salts.

**Claim 25 (cancelled)**

**Claim 26 (currently amended)**

A pharmaceutical ~~An antitumoral~~ composition comprising an antitumorally effective amount of a compound of formula (II<sub>A</sub>) of claim 24 and an inert carrier.

**Claim 27 (currently amended)**

A method of treating colon cancer tumors in warm-blooded animals comprising administering to warm-blooded animals in need thereof an ~~antitumorally~~ effective amount of a compound of claim 24 to treat colon cancer.

**AMENDMENTS TO THE CLAIMS**

**Claims 1 to 4 (cancelled)**

**Claim 5 (currently amended)**

A compound of claim 24 which is selected from the group consisting of

(5R)-5-ethyl-9,10-difluoro-5-hydroxy-12-(2-trimethylsilylethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino [3',4':6,7]-indoloizino[1,2-b]quinoline-3,15-dione;

~~(5R)-5-ethyl-5-hydroxy-12-(2-trimethylsilylethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino [3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione.~~

**Claims 6 to 23 (cancelled)**

**Claim 24 (currently amended)**

A compound selected from the group consisting of the formula

